EMEA-003243-PIP01-22 - paediatric investigation plan

toripalimab

Key facts

• Active substance:
  toripalimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0408/2022
• PIP number:
  EMEA-003243-PIP01-22
• Pharmaceutical form(s):
  Concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of all conditions in the category of malignant neoplasms (except CNS, haematopoietic and lymphoid tissue and melanoma)
• Route(s) of administration:
  Intravenous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  09/09/2022
• Compliance check done:
  No

Decision

P/0408/2022 : EMA decision of 9 September 2022 on the granting of a product specific waiver for toripalimab (EMEA-003243-PIP01-22)

Adopted Reference Number: EMA/709249/2022